EP2088990A1 - Préparations dermatologiques contenant des phosphatidylcholines hydrogénées - Google Patents

Préparations dermatologiques contenant des phosphatidylcholines hydrogénées

Info

Publication number
EP2088990A1
EP2088990A1 EP07801360A EP07801360A EP2088990A1 EP 2088990 A1 EP2088990 A1 EP 2088990A1 EP 07801360 A EP07801360 A EP 07801360A EP 07801360 A EP07801360 A EP 07801360A EP 2088990 A1 EP2088990 A1 EP 2088990A1
Authority
EP
European Patent Office
Prior art keywords
hydrogenated
active
incorporated
cosmetic
weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP07801360A
Other languages
German (de)
English (en)
Inventor
Eckart Voss
Rolf-Dieter Schilling
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Maxim Markenprodukte & Co KG GmbH
Original Assignee
Maxim Markenprodukte & Co KG GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE200610045388 external-priority patent/DE102006045388A1/de
Priority claimed from DE102006045389A external-priority patent/DE102006045389A1/de
Application filed by Maxim Markenprodukte & Co KG GmbH filed Critical Maxim Markenprodukte & Co KG GmbH
Publication of EP2088990A1 publication Critical patent/EP2088990A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/14—Liposomes; Vesicles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/55—Phosphorus compounds
    • A61K8/553—Phospholipids, e.g. lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/007—Preparations for dry skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations

Definitions

  • the invention relates to topical dermatological preparations for applications in cosmetics and medicine in which the active ingredients are present as a saturated concentrate in the multilamellar layers of hydrogenated phosphatidylcholines (PC), a process for their preparation and their use.
  • PC hydrogenated phosphatidylcholines
  • Cosmetic preparations are according to the European Cosmetics Regulation exclusively or predominantly intended to be applied externally to the body of man to z. B. cleaning, stabilizing, vitalizing and deodorizing u. a. to act on the skin, oral cavity, nails and hair.
  • the usual dermatological preparations for applications in cosmetics and medicine are usually a mixture of active ingredients and excipients, their mode of action as a single substance or as a mixture of substances, their absorption in the body, their rate of release, their place of release and the site of action often is uncertain. This may be tolerated in cosmetics with intact skin because of their high barrier and repair performance, but may cause the intended positive effect of the drug in its opposite with damaged skin.
  • Object of the present invention are new dermatological preparations in which the proportion of excipients in relation to the active ingredients is significantly reduced and undesirable effects are minimized.
  • New topical dermatological preparations were found; containing
  • Phosphatidylcholins is incorporated, and as additives water, solubilizers and cosmetic auxiliaries and supplements, wherein the sum of the ingredients 100 wt.% Results.
  • the preparations according to the invention may contain all additives known per se in cosmetics and medicine.
  • Preferred dermatological preparations may contain from 20 to 40% by weight of hydrogenated phosphatidylcholine,
  • Liposome is incorporated, and wherein the active substance has a predominantly lipophilic character, and as additives water, solubilizers and cosmetic auxiliaries and supplements, wherein the sum of the components 100 wt.% Results.
  • Hydrogenated phosphatidylcholines are present in a lamellar layered structure.
  • the active ingredients are incorporated to the saturation limit in the layers of hydrogenated phosphatidylcholines. This limit varies depending on the active substance property and is the higher, the more lipophilic the active ingredients are.
  • DE 198 57 491 A1 discloses skin protection preparations for the prevention of skin damage by UV filters while at the same time strengthening the lipid barrier by means of so-called hydrogenated phosphatidylcholines.
  • the proportion of hydrogenated phosphatidylcholines is 0.1 to 10 wt.%. and at 15 UV filters 0.5 to 30 wt.% And of the UV filters, portions are present inside and outside the PC layers.
  • active substances are applied virtually completely as active substances incorporated as hydrogenated phosphatidylcholines (HPC). Since these HPC are stored in the uppermost skin layers, where they remain due to their material properties and release the stored active ingredients by slow diffusion from the HPC matrix, one obtains in this way a kind of depot effect of the stored active substance on the skin. In addition, the stored active substances are largely protected from interaction with other active substances and with atmospheric oxygen, which leads to an improved effect.
  • the preparations according to the invention therefore have fewer active ingredients and do not require penetration-enhancing vehicles.
  • the preparations according to the invention are superior to the known ones in two ways: on the one hand, they have less active ingredient, on the other hand they require less auxiliaries. Both lead to more efficient and compatible preparations.
  • Hydrogenated phosphatidylcholines in the context of the present invention are generally phosphatidylcholines known per se. Their manufacturing process, for example, proceeds via fractionation of soy lecithin
  • DMS dermomembrane systems
  • Hydrogenated phosphatidylcholines for the present invention may be represented by the general formula
  • n is one of the numbers 14 or 16, will be described.
  • Active substances in the context of the present invention may be cosmetic and / or medicinal active substances.
  • all hydrophilic or lipophilic active ingredients customary in cosmetics and dermatics can be used as active ingredients in the preparations according to the invention, but the loading limit for lipophilic active ingredients is substantially higher.
  • Cosmetic active substances in the context of the present invention preferably contain lipophilic active substances which are already effective at low concentrations, but also the UV filters required for higher concentrations in 5 light stabilizers.
  • Medicinal active ingredients in the context of the present invention are known active substances for the treatment of autoimmune diseases, infectious diseases of the skin, inflammatory diseases of other cause or unclear aetiology, erythematosquamous dermatoses, Papulo lichenoid dermatoses, skin tumors, intolerance reactions of the skin, physical and chemical damage to the skin, hereditary Skin diseases, disorders of the appendages and / or pigmentary disorders.
  • the preparations according to the invention can very particularly advantageously be used, for example, for cosmetic or medical sunscreens. These are mostly emulsions or gels that are applied to the skin to protect it from the harmful effects of UV radiation.
  • UV protection factor for UV-B rays
  • UV-ABalance for UV-A protection
  • UV filter combination designed to reduce the UV rays as much as possible.
  • effective UV-A filters rather than UV-B filters, are required for daily care, whereas in sunscreens it is reversed.
  • SPF 4 sun protection factors
  • U. VA balance of 100% and more is needed.
  • Epidermological studies have shown that with consistent use of such efficient amounts of UV filters, wrinkles as a sign of visible aging are greatly reduced.
  • the choice of suitable UV-A filters is not great here, because many are limited because of their low solubility or their deactivation-leading interaction with other filters.
  • the preparations according to the invention eliminate these limitations.
  • UV filters in the context of the present invention may be all substances approved in the Colipa positive list UV-A and UV-B filters. It is possible that a mixture of UV-A and UV-B filters is present in the topically acting sunscreen agents according to the invention.
  • UV-A and UV-B filters may be mentioned as preferred: 1- (4'-isopropylphenyl) -3-phenylpropane-1,3-dione, 1- (4-tert-butylphenyl) -3- (4-methoxyphenyl ) -propane-1,3-dione, 2,4-2,4-dihydroxybenzophenone, 2-hydroxy-4-methoxybenzophenone, 2,2'-dihydroxy-4,4'-dimethoxybenzophenone, 4- (bis (2-hydroxypropyl) amino) benzoic acid ethyl ester, 2-ethylhexyl 4-dimethylaminobenzoate, 3- (4-methylbenzylidene) bornan-2-one, 3-benzyliden-bornan-2-one, 4-methoxycinnamic acid 2-ethylhexyl ester, 4-methoxycinnamic acid propyl ester, A-methoxycinnamic acid iso
  • UV and light filters from the group of dibenzoylmethane, benzophenone, cinnamic acid, triazine, the
  • Urocaninic acid compounds and from the group of the oxides of zinc and titanium, wherein the filters may be present individually or in a mixture.
  • the UV filters are methylene-bis-benzotriazolyl tetramethylbutylphenol (Tinosorb® M) and ethylhexyl-oxyphenol methoxyphenyl triazine (Tinosorb® S).
  • Light stabilizers in the context of the present invention can be any light stabilizers in the context of the present invention.
  • UV filters 5 to 50 wt.% Of hydrogenated phosphatidylcholines and 5 to 50 wt.% Of one or more UV filters in combination, wherein the UV filter is incorporated into the layered structure of the hydrogenated PC, and as additives water, solubilizers and cosmetic auxiliary and
  • Preferred light stabilizers in the context of the present invention may comprise 10 to 40% by weight of hydrogenated phosphatidylcholines and 10 to 40% by weight of one or more UV filters in combination, wherein the UV filter is incorporated in the multilamellar layers of the hydrogenated PC, and wherein the UV filter has a predominantly lipophilic character and as additives water, solubilizers and cosmetic auxiliaries and active ingredients, and wherein the sum of the components 100 wt.% Results.
  • the preparations according to the invention can very particularly advantageously be used, for example, for cosmetic or medical preparations against dry skin (moisturizers) and as anti-wrinkle agents,
  • Humectants and / or anti-wrinkle agents within the scope of the present invention
  • the humectants and / or anti-wrinkle agents according to the invention can contain all additives known per se in cosmetics and dermatology.
  • Preferred humectants and / or anti-wrinkle agents in the context of the present invention can be any suitable humectants and / or anti-wrinkle agents in the context of the present invention.
  • the preparations according to the invention are surprisingly particularly advantageous against dry skin.
  • the hydrogenated phosphatidylcholines have a reinforcing effect on the skin lipid barrier and a favorable effect on skin that is too dry.
  • highly potent skin moisturizers such.
  • hyaluronic acid and panthenol are incorporated according to the invention in the lamellae of the hydrogenated liposomes and thereby protracted their moisturizing and anti-wrinkle effect and targeted where it is needed, unfold.
  • the preparations according to the invention are without emulsifiers.
  • Emulsifiers are known to wash natural skin fats out of the skin and are therefore not well suited for the treatment of dry skin.
  • humectants vitamin E vitamin E
  • vitamin A lipophilized hyaluronic acid
  • DSH-CM ® panthenol, glycerol and urea and called anti-wrinkle agents ubiquinone or ursolic acid or palmitoyl-pentapeptide
  • additives for the preparations according to the invention may be, for example, oils and fats, salts, moisturizing substances, emulsifiers, preservatives and / or dermatological or cosmetic supplements.
  • fats and oils such as.
  • MCT medium-chain triglycerides
  • MCT medium-chain triglycerides
  • Salts These are to be understood in the context of the skin protection preparations according to the invention salts of sodium, potassium, magnesium, calcium, zinc and choline. Preference is given to fluorides, chlorides, sulfates, phosphates, 2-amino-ethyl phosphates, Giycolate, lactates, citrates, succinates, malates, fumarates, Monomethylfumarate, Monoethylfumarate, tartrates or their
  • the mixtures may, for. B. also be of natural origin
  • Humectants In the context of the skin protection preparations according to the invention are physiologically acceptable polyols, urea or mixtures thereof to understand each other. Typical representatives are glycol, propylene glycol, butylene glycol, hexylene glycol, glycerol, inositol (inositol), sorbitol (sorbitol), mannitol, palatinit, maltodextrin, dextrin, cyclodextrin, 0 glucose, fructose, lactose, mannose, galactose and other saccharides.
  • glycerin glycerin, propylene glycol, pentylene glycol and urea.
  • Dermatological and cosmetic supplements of the 5 formulations of the invention are skin wrinkle reducing agents such.
  • Short-chain peptides argireline, antarcticins and lipophilized peptides (such as palmitolyl-pentapeptide (Matrixyl®)), skin-structurally-improving peptides (collagens such as atelocollagen, desamidocollagen, etc.), skin-protecting lipids and waxes such as Mono-, de-, tri-, and 0 polyglycerides of ricinoleic, 12-hydroxystearic and 11-hydroxypalmitic acid,
  • Castor oil hydrogenated castor oil, octyl dodecyl ricinoleic acid, octyl 12-hydroxy stearate, beeswax, Japan wax, carnauba wax, cetyl palmitate, cocoa butter, jojoba oil, shea butter, squalene, Squalane, cholesterol, cholesteryl sulfate, phytosterols, lanolin, lanolin alcohols and their derivatives, ceramides, sphingolipids, sphinganine, sphingosine, sphingosine 1-phosphate, sphingomyelin, C 12 -C 15 alkyl benzoate, linoleic acid methyl and ethyl ester, linoleic acid mono-, di and triglycerides.
  • vitamins and provitamins especially A, B complex, C 1 E, D and their usual derivatives such as vitamin A acid, vitamin A acetate, vitamin A palmitate, vitamin C palmitate, vitamin C phosphate, Vitamin E acetate, palmitate and linoleate, alfacalcidol, calcitriol, colecalciferol, ergocalciferol, folic acid, transcalcifediol, calciprotriol,
  • antifungals eg, econazole, bifonazole, isoconazole, oxiconazole, tioconazole, fenticonazole, clotrimazole, miconazole, ketoconazole, itracon
  • Anti-inflammatory substances eg glucocorticoids and their derivatives such as triamcinolone acetonide, bufexamac, chamomile extract, witch hazel extract, tannins, bisabolol, acetylsalicylic acid, allantoin), immunosuppressants (eg methotrexate, cyclosporin), retinoids (eg retinol,
  • Retinol palmitate isotretinoin, acitretinoin, tazarotene
  • anti-infective agents eg, clindamycin, tetracyclines
  • cytokines eg, interleukins, interferons, tumor necrosis factors
  • antiseptics eg, chlorhexidine, benzalkonium chloride, 8-hydroxyquinolines, ethacridine, hexetidine , Acriflavinium chloride, benzoxonium chloride, bibrocathol,
  • Dequalinium salts ethanol, 2-propanol, 1-propanol, azelaic acid, resorcinol, Triclosan, farnesol, diglycerol monocaprate, colloidal silver, silver chloride, gentamycin, salicylic acid, ozonated olive oil, benzoyl peroxide), antivirals (eg, acyclovir, penciclovir, foscarnet sodium, idoxuridine, trifluridine, tromantadine, vidarabine), astringents (e.g. Tannin, oak bark extract, bismuth gallate),
  • antivirals eg, acyclovir, penciclovir, foscarnet sodium, idoxuridine, trifluridine, tromantadine, vidarabine
  • astringents e.g. Tannin, oak bark extract, bismuth gallate
  • Extracts with specific effects eg aloe vera extract, green tea extract, algae extract, echinacea extract, arnica extract, cucumber extract, hops extract, carrot extract, bran extract, witch hazel extract, yeast extract, gingko biloba extract
  • vegetable oils with specific effects eg eg rosemary oil, chamomile oil, sage oil, calendula oil, lavender oil, St. John's wort oil,
  • Lemon balm oil seabuckthorn oil, tea tree oil, cedar wood oil, cypress oil
  • oils with a high content of esterified highly unsaturated (essential) fatty acids (eg evening primrose oil, currant oil, borage oil, rosehip oil, soybean oil, fish oil) and barrier-stabilizing acids (eg linoleic acid, 12-hydroxystearic acid, stearic acid, isostearic acid,
  • Palmitic acid, 11-hydroxypalmitic acid, protein hydrolyzate condensates (“lipacides”, e.g., palmitoyl wheat protein hydrolyzate, dipalmitoyl hydroxyproline, N-palmitoyl glutamic acid), hyaluronic acid) and specific effecting substances (e.g., 1,2-dithiacyclopentane-3-valeric acid, adapalene, ammoidin , Tioxolone, Minoxidil, Fluorouracil).
  • lipacides e.g., palmitoyl wheat protein hydrolyzate, dipalmitoyl hydroxyproline, N-palmitoyl glutamic acid), hyaluronic acid
  • specific effecting substances e.g., 1,2-dithiacyclopentane-3-valeric acid, adapalene, ammoidin , Tioxolone, Minoxidil, Fluorouracil.
  • the active substances include substances capable of preventing heavy metal cations from penetrating the skin (eg EDTA, 1-hydroxyethane-i, 1-diphosphonic acid, trimethylammonioacetate, cm-glucan, chitosan, polyvinylalcohol, polyvinylpyrrolidone , Bentonites, kaolin, cyclodextrides, pectins and their derivatives, alginic acid and alginates,
  • substances capable of preventing heavy metal cations from penetrating the skin eg EDTA, 1-hydroxyethane-i, 1-diphosphonic acid, trimethylammonioacetate, cm-glucan, chitosan, polyvinylalcohol, polyvinylpyrrolidone , Bentonites, kaolin, cyclodextrides, pectins and their derivatives, alginic acid and alginates,
  • Polysaccharides and their derivatives eg microcrystalline cellulose, cellulose ethers, methylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, carmellose, carboxymethylcellulose, tragacanth, tragacanthine), carrageenans, xanthan, locust bean gum, guar gum and its derivatives, arabic gum, polyacrylates and their copolymers).
  • Supplements include mutatis mutandis, covering substances and pigments such. Magnesium oxide, magnesium carbonate, magnesium aluminum silicate, magnesium stearate, magnesium isostearate, talc, calcium carbonate, zinc oxide, zinc carbonate, zinc stearate, zinc laurate,
  • Alumina, aluminosilicates, silica, aerosil, boron nitride, mica and minerals, pigments optionally associated with known compatible dyes or tanning agents, e.g. As dihydroxyacetone, may have, in the skin protection preparations according to the invention the
  • I O meaning, on the one hand to protect against external pollutants, on the other hand to cover localized skin damage or skin abnormalities, in order to protect the skin against corresponding, psychologically induced reactions (scratching, squeezing, etc.).
  • Combination be included in the skin protection preparations of the invention. If an adjustment of the pH due to acidic active ingredients is necessary, this can be done by means of indifferent inorganic bases such. For example, sodium hydroxide, potassium hydroxide, or organic bases such. B. 0 triethylamine or triethanolamine done.
  • Particularly preferred active ingredients are linoleic acid and linolenic acid and their esters, palmitic acid, stearic acid and their esters, natural unsaturated oils and fats such as shea butter, jojoba oil, avocado oil, evening primrose oil, currant seed oil, rosehip oil, fish oil, as well as squalane, cholesterol, vitamins of the A-, C- , E-5 and D series and their acetates, palmitates, stearates and linolates or phosphates.
  • proteins such as collagens, short-chain peptides such as Argireline, etc. 0
  • the active ingredients are not in liquid form, the active compounds are supplied in dissolved form of high-pressure homogenization by the novel process.
  • a suitable solvent must be determined depending on the active ingredient, A suitable solvent should be as little lipophilic as possible, but have a high solubility for the active ingredient.
  • the homogenization under high pressure in the first stage of the process according to the invention can be carried out in a manner known per se. In general, a homogenization time of about 5 to about 15 minutes is sufficient.
  • hydrogenated phosphatidylcholines are homogenized under high pressure with active ingredients, the latter are incorporated in the multilamellar layers of the hydrogenated liposome. In the process according to the invention this takes place up to the saturation limit of the active substances in the hydrogenated phosphatidylcholines in order to occupy all free binding sites in the intermediate layers. Subsequently, the hydrogenated phosphatidylcholine active substance concentrates thus prepared are mixed with suitable other components to produce the final product. This is how dermatics and
  • Cosmetics which have many advantages over "normal" preparations made with the same active ingredients in the same concentration.
  • the preparation of the sunscreen agents according to the invention takes place in two stages. First, the separate incorporation of the active ingredients in the hydrogenated phosphatidylcholines in the premix to the saturation limit according to the method of high-pressure homogenization described above. This premix is then added to the end products in the required amount. This results in a much higher distribution ratio of active ingredient to hydrogenated phosphatidylcholine than in the conventional procedure which homogenizes the active ingredients in the final product concentration together with all the excipients. This higher distribution quotient has numerous beneficial consequences.
  • the active ingredient is stably incorporated into the DMS and is therefore no longer available for alternative forms of dispersion.
  • Alternative forms of dispersion are z.
  • By means of such alternative emulsions at least a large part of the active ingredient is emulsified in the conventional process and thereby offered as in classical emulsions.
  • the present invention is also the use of topically acting dermatological preparations with
  • Phosphatidylcholins is incorporated, and as additives water, solubilizers and cosmetic auxiliary and
  • the preparations according to the invention can preferably be used in light stabilizers. Particularly preferred in the context of the present invention is the use of the preparations according to the invention, the 5 to 50 wt.% Hydrogenated Phosphatidyicholine and 5 to 50 wt.% Of one or more UV filters in combination, wherein the UV filter in the layered structure of the hydrogenated Phosphatidylcholins is incorporated, and as additives water, solubilizers and cosmetic auxiliaries and active ingredients, and wherein the sum of the components 100 wt.% Results as a light stabilizer.
  • UV filters methylene-bis-benzotriazolyl tetramethylbutylphenol and / or ethylhexyl-oxyphenol methoxyphenyl triazine can be used.
  • the preparations according to the invention can preferably be used in skin moisturizers and / or anti-wrinkle agents.
  • moisturizing and / or anti-wrinkling active ingredient being incorporated in the layered structure of the hydrogenated phosphatidylcholine and containing water, solubilizers and cosmetic auxiliaries and active substances as additives; Sum of ingredients 100 wt.% Results.
  • the preparations according to the invention can preferably also be used in medical preparations.
  • the preparations according to the invention can preferably be used in gels, creams and lotions.
  • Phase is formed, cooled, and the content of methylene-bis-benzotriazolyl tetramethylbutylphenol determined by UV measurement.
  • the oil phase of 19 wt.% Caprylic / capric triglyceride, 2.5 wt.% Coconut oil, 2 wt.% Jojobaö ⁇ , 0.1 wt.% Xanthan gum and 0.2 wt.% Carbomer is melted, cooled to 30 0 C.
  • the water phase of 45.6 wt.% Water, 2.5 wt.% Pentylene glycol, 0 2 wt.% Glycerol and 0.1 wt.% Of a 32 percent.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Cosmetics (AREA)

Abstract

Des préparations dermatologiques à usage local, dans lesquelles les principes actifs sont présents sous la forme d'un concentré saturé dans les couches multilamellaires de phosphatidylcholines hydrogénées, peuvent être utilisées dans le domaine de la cosmétique et de la médecine.
EP07801360A 2006-09-26 2007-09-20 Préparations dermatologiques contenant des phosphatidylcholines hydrogénées Withdrawn EP2088990A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE200610045388 DE102006045388A1 (de) 2006-09-26 2006-09-26 Dermatologische Zubereitungen
DE102006045389A DE102006045389A1 (de) 2006-09-26 2006-09-26 Dermatologische Feuchthaltemittel
PCT/DE2007/001699 WO2008040303A1 (fr) 2006-09-26 2007-09-20 Préparations dermatologiques contenant des phosphatidylcholines hydrogénées

Publications (1)

Publication Number Publication Date
EP2088990A1 true EP2088990A1 (fr) 2009-08-19

Family

ID=38938285

Family Applications (1)

Application Number Title Priority Date Filing Date
EP07801360A Withdrawn EP2088990A1 (fr) 2006-09-26 2007-09-20 Préparations dermatologiques contenant des phosphatidylcholines hydrogénées

Country Status (2)

Country Link
EP (1) EP2088990A1 (fr)
WO (1) WO2008040303A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102009008940A1 (de) 2009-02-13 2010-08-19 Rolf Ludl Hautpflegende Kombination aus Hyaluronsäuregel und Creme in separaten Zubereitungen
US9549891B2 (en) 2012-03-19 2017-01-24 The Procter & Gamble Company Superabsorbent polymers and sunscreen actives for use in skin care compositions
WO2017004108A1 (fr) 2015-06-29 2017-01-05 The Procter & Gamble Company Polymères superabsorbants et poudres d'amidon utilisables dans des compositions de soins de la peau
KR20210120633A (ko) 2020-03-27 2021-10-07 (주)아모레퍼시픽 시트형 마스크 겔 조성물, 이를 포함하는 마스크 시트 및 마스크 시트의 제조방법
CN113967175A (zh) * 2020-07-24 2022-01-25 株式会社爱茉莉太平洋 片型面膜凝胶组合物、包含其的面膜片及面膜片制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19857489A1 (de) * 1998-12-14 2000-06-15 Hans Lautenschlaeger Ölhaltige Hautschutzpräparate zur Prävention von Hautschäden
WO2001062222A2 (fr) * 2000-02-25 2001-08-30 Kuhs Kosmetik Gmbh & Co. Kg Composition cosmetique
US9283162B2 (en) * 2001-10-26 2016-03-15 Taiyo Kagaku Co., Ltd. Composition for oily foamable aerosol

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2008040303A1 *

Also Published As

Publication number Publication date
WO2008040303A1 (fr) 2008-04-10

Similar Documents

Publication Publication Date Title
DE69500077T2 (de) Kosmetische und dermatologische Zusammensetzung bestehend aus einem öligen Kügelchen und mit lamellaren Flüssigkristallen beschichtete Öl in Wasser Emulsion
EP0814753B1 (fr) Gels cosmetiques ou dermatologiques a base de microemulsions
EP0783882B1 (fr) Emulsions cosmétiques et dermatologiques pour la protection solaire
DE19619837B4 (de) Kosmetische oder pharmazeutische Zubereitungen mit vermindertem Klebrigkeitsgefühl
DE4320871C2 (de) Kosmetische und dermatologische Zubereitungen mit einem Gehalt an delta-Aminolävulinsäure
WO2000037042A1 (fr) Gels contenant de la lecithine, ou micro-emulsions huile dans l'eau, contenant de la lecithine, de basse viscosite, a usage cosmetique ou pharmaceutique
DE4420625C1 (de) Wirkstoffkombination mit einem Gehalt an Glycerylalkylethern und kosmetische und dermatologische Zubereitungen, solche Wirkstoffkombinationen enthaltend
WO1998015255A1 (fr) Microemulsions cosmetiques ou dermatologiques
DE19802206A1 (de) Lipidreduzierte, fließfähige Zubereitungen
EP0780112A1 (fr) Procédé de fabrication d'émulsions huile dans eau ou huile/eau/huile ainsi que les émulsions ainsi obtenues
DE69519952T2 (de) Selbstbräunende kosmetische Mittel enthaltend Dihydroxyaceton
EP2088990A1 (fr) Préparations dermatologiques contenant des phosphatidylcholines hydrogénées
EP1635776B9 (fr) Systemes de proteines de transfert lipidique et leur application dermatologique/cosmetique
DE4230076C2 (de) cis-Urocaninsäure als Antioxidans
DE4021083A1 (de) Phospholipidformulierungen und ihre verwendung fuer die zubereitung liposomaler medizinischer und kosmetischer baeder
WO2014183973A1 (fr) Préparations stabilisées à teneur en acide ascorbique et en ions phosphate
DE602005005082T3 (de) Benetzungsmittel auf basis einer mischung von monoestern und diestern von butylenglycol
DE102005030864A1 (de) Kosmetische Zubereitung zur Verbesserung der Hautfeuchtigkeit
DE102009008940A1 (de) Hautpflegende Kombination aus Hyaluronsäuregel und Creme in separaten Zubereitungen
EP3773459B1 (fr) Procédé pour produire une formulation de départ pour une préparation dermatologique de protection contre la lumière et pour produire une préparation dermatologique de protection contre la lumière
EP0713380B1 (fr) Preparation fonctionnelle oxygenee contenant des phospholipides et du fluorocarbone
DE102005051862A1 (de) Emulsion enthaltend 1,2-Alkandiole und polare Ölkomponenten
DE19857491A1 (de) Hautschutzpräparate zur Prävention von Hautschäden mit UV-Filtern
EP0783881A2 (fr) Compositions cosmétiques et dermatologiques de protection solaire contenant des micropigments inorganiques hydrophobes
WO2019149509A1 (fr) Complexe de principes actifs pour préparations cosmétiques

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20090417

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

RIN1 Information on inventor provided before grant (corrected)

Inventor name: SCHILLING, ROLF-DIETER

Inventor name: VOSS, ECKART

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20110210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20130402